Burning Rock Dx(US:BNR) Jin Rong Jie·2025-07-29 14:02Core Viewpoint - BNR (Burning Rock Biotech) shows positive financial growth with a revenue increase and a significant reduction in net loss, indicating potential for investment opportunities in the precision oncology market [1][2]. Financial Performance - As of March 31, 2025, BNR reported total revenue of 133 million RMB, representing a year-on-year growth of 5.94% [1]. - The net loss attributable to the parent company was 13.5 million RMB, which reflects a year-on-year improvement of 88.89% [1]. Upcoming Events - BNR is scheduled to disclose its mid-year report for the fiscal year 2025 on August 28, with the actual date subject to company announcement [1]. Company Background - Founded in 2014, BNR focuses on providing clinically valuable next-generation sequencing (NGS) for precision oncology, with a mission to "guard the light of life with science" [1]. - The company has a leading market share in tumor patient testing in China and collaborates with global anti-tumor pharmaceutical companies on biomarkers and companion diagnostics [1]. Regulatory Milestones - In July 2018, BNR received the first NGS testing kit approval from the National Medical Products Administration (NMPA) in China, marking a significant milestone in the in vitro diagnostic field [2]. - BNR's laboratories in Guangzhou and California have obtained CLIA and CAP laboratory quality system certifications, ensuring high standards in their testing processes [2].